Trial Profile

An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Patients With Myelofibrosis

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 31 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Imetelstat (Primary) ; Ruxolitinib (Primary)
Indications Myelofibrosis
Focus Adverse reactions; Therapeutic Use
Acronyms IMproveMF
Sponsors Geron Corporation

Most Recent Events

26 Aug 2026 Status changed from recruiting to active, no longer recruiting.
06 Jan 2026 Planned number of patients changed from 51 to 36.
08 Dec 2025 According to a Geron Corporation media release, data from this study presented at the 67th American Society of Hematology (ASH) 2025 Annual Meeting being held in Orlando, FL.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com